A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) (Q64659815)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) |
clinical trial |
Statements
A Multicenter Randomized Phase III Study to Compare the Combination Trastuzumab and Capecitabine, With or Without Pertuzumab, in Patients With HER2-Positive Metastatic Breast Cancer That Have Progressed After One Line of Trastuzumab-Based Therapy in the Metastatic Setting (PHEREXA) (English)
0 references
26 January 2010
0 references
29 May 2015
0 references
452
0 references
18 year
0 references